COMMUNIQUÉS West-GlobeNewswire

Daxor Expands Blood Volume Analysis Services at Major Midwest Healthcare Center

28/02/2025 - 14:00

Premier 735-Bed Healthcare Facility Implements ezBVA Lab Service to Enhance Cardiovascular Outpatient Care Oak Ridge, TN, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), Daxor, the global leader in [...]

Alignment Healthcare to Present at the Leerink Global Healthcare Conference and KeyBanc Capital Markets Healthcare Forum

28/02/2025 - 14:00

ORANGE, Calif., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Alignment Healthcare, Inc. (NASDAQ: ALHC), today announced that it will present at the following conferences: Leerink Global Healthcare Conference on Tuesday, March 11, [...]

Lifeward to Report Fourth Quarter and Fiscal Year-End 2024 Financial Results on March 7, 2025

28/02/2025 - 14:00

MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of [...]

Jasper Therapeutics Announces Late-Breaking Briquilimab Presentation at the American Academy of Dermatology (AAD) Annual Meeting

28/02/2025 - 14:00

REDWOOD CITY, Calif., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting [...]

Johnson & Johnson’s DARZALEX® (daratumumab) subcutaneous-based regimen receives positive CHMP opinion for patients with newly diagnosed multiple myeloma, regardless of transplant eligibility

28/02/2025 - 14:01

If approved, daratumumab will be the only anti-CD38 available for all patient types across newly diagnosed multiple myeloma, cementing daratumumab as a foundational therapy in the frontline setting. Recommendation [...]

Outlook Therapeutics® Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration

28/02/2025 - 14:05

ISELIN, N.J., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United Kingdom (UK) for the [...]

CHMP recommends EU approval of Roche’s Columvi combination for people with relapsed or refractory diffuse large B-cell lymphoma

28/02/2025 - 14:15

Columvi plus chemotherapy showed a 41% reduction in the risk of death in the pivotal phase III STARGLO study 1,2 DLBCL—an aggressive disease with a high risk of progression—remains an area of high unmet need, especially [...]

Safety Shot, Inc. Appoints CORE IR & PR for Investor Relations, Shareholder Communications and Public Relations Services

28/02/2025 - 14:30

CORE IR & PR to support strategic communications in conjunction with corporate development and commercial activities SCOTTSDALE, Ariz., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Safety Shot, Inc. (Nasdaq: SHOT) ("Safety [...]

Nexalin Technology Announces Initiation of Patient Recruitment for UCSD’s TBI & PTSD Clinical Study Following IRB Approval

28/02/2025 - 14:30

HALO™ Clarity Devices Successfully Shipped for First Phase of Clinical Trials HOUSTON, TX, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) the leader in Deep [...]

Trinity Biotech Announces Additional Funding To Support Transformation Plan & Continued Development of the Company’s Continuous Glucose Monitoring Technology

28/02/2025 - 14:30

DUBLIN, Ireland, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable [...]

Noom Expands into Hormone Replacement Therapy to Support Women’s Health and Well-being

28/02/2025 - 14:37

Noom + HRT Rx blends Noom’s proven behavior change program with HRT medication to achieve whole-person health The new offering builds on the rapid growth of the company’s medically assisted weightloss franchise, which [...]

TREMFYA® (guselkumab) receives positive CHMP opinion for treatment of adult patients with moderately to severely active ulcerative colitis

28/02/2025 - 14:43

Recommendation based on the findings from the Phase 3 QUASAR programme in ulcerative colitis 1 Beerse, Belgium (28 February 2025) – Johnson & Johnson today announced that the Committee for Medicinal Products for [...]

AIM announces Paul Goepfert, MD, as the principal investigator for the planned clinical study of Ampligen and FluMist as a vaccine for avian influenza

28/02/2025 - 14:45

Proposed study of Ampligen as a vaccine adjuvant to increase cross-reactivity to influenza strains OCALA, Fla., Feb. 28, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today [...]

Ultimovacs ASA: Approval and publication of prospectus

28/02/2025 - 14:45

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR ANY JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. [...]

InflaRx to Showcase Vilobelimab’s Role in Immuno-Dermatology at the 2025 AAD Annual Meeting

28/02/2025 - 15:00

JENA, Germany, Feb. 28, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced acceptance of all [...]

WORK Medical Technology Group LTD Announces Strategic Partnership with Shanghai Chartwell Medical Device Co., Ltd.

28/02/2025 - 15:00

Hangzhou, China, Feb. 28, 2025 (GLOBE NEWSWIRE) -- WORK Medical Technology Group LTD (Nasdaq: WOK) (“WORK Medical” or the “Company”), a supplier of medical devices, through its subsidiary, Work (Hangzhou) Medical [...]

Arcutis to Present Two Posters at the 83rd American Academy of Dermatology Annual Meeting

28/02/2025 - 15:00

One poster will share pooled INTEGUMENT data of ZORYVE ® (roflumilast) cream 0.15% in atopic dermatitis (AD) in patients with prior inadequate response, intolerance, and/or contraindications to topical treatments [...]

Novartis data presentations at AAAAI and AAD underscore commitment to advancing treatment of hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU)

28/02/2025 - 15:00

Two-year efficacy and safety data analyses from Phase III SUNSHINE and SUNRISE trials of continuous Cosentyx ® (secukinumab) treatment in HS to be presented New analyses of 52-week data from Phase III REMIX pivotal [...]

Alumis Announces Late-Breaker Psoriasis Presentation of 52-week Phase 2 OLE Data for ESK-001 at 2025 American Academy of Dermatology Annual Meeting and Accelerated Topline Phase 3 Data Readout

28/02/2025 - 15:08

– Late-breaking oral presentation to highlight 52-week data of ESK-001 in a Phase 2 open-label extension (OLE) study in adults with moderate-to-severe plaque psoriasis – – Additional Phase 2 e-poster presentations to [...]